Amid positive trial results, ZYNLONTA has already received accelerated approval from the FDA and conditional approval from ...

As of Wednesday, December 17, Estrella Immunopharma, Inc.’s ESLA share price has surged by 7.90%, which has investors ...

Incyte has won European Commission expanded approval of its Minjuvi cancer drug for certain patients with one of the most-common subtypes of non-Hodgkin lymphoma.

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory ...

In the rapidly evolving field of pharmaceuticals, China's role as a hub for innovative drug development continues to expand, particularly in its outbound strategies. As we approach the end of 2025, ...

People aged 80 and older with a common type of lymphoma can take a half-dose of chemotherapy and be cured or significantly ...

Incyte (INCY) announced that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”), a clinical stage biotechnology ...

Overall, BTK inhibitors and ICH-related therapies sit in a space with strong scientific momentum but notable hurdles. Growing prevalence of B-cell cancers, autoimmune disorders, and neurological ...

New ultrasound technology developed at Johns Hopkins can distinguish fluid from solid breast masses with near perfect ...

While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...